NYAMYC SUMMARY
Nystatin is a polyene antifungal antibiotic obtained from Streptomyces nursei.
Nyamyc™ (Nystatin Topical Powder, USP) is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species.
This preparation is not indicated for systemic, oral, intravaginal or ophthalmic use.
|
NEWS HIGHLIGHTS
Published Studies Related to Nyamyc (Nystatin Cutaneous)
Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus successfully treated by oral voriconazole and nystatin packing. [2011.08]
Paecilomyces lilacinus causes multiple diseases in humans, especially in immunocompromised patients... lilacinus infection that were treated by oral voriconazole.
Clinical Trials Related to Nyamyc (Nystatin Cutaneous)
Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis [Completed]
The purpose of this study was to see which one of two medicines (topical gentian violet [GV]
or nystatin oral suspension) was better than the other in treating Oral Candidiasis (OC).
This was measured by whether the study participant still had OC or sores in his/her mouth
after 14 days of treatment. Also, safety and tolerability of GV and nystatin in the
treatment of OC were assessed.
Effect of Aqueous Extract of Garlic and Nystatin Mouthwash in Denture Stomatitis [Completed]
The aim of the present study was to compare the effect of aqueous extract of garlic with
nystatin mouthwash in denture stomatitis.
Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections [Not yet recruiting]
A Study of Nystatin in HIV-Infected Patients [Completed]
To evaluate the clinical toxicity, safety, and potential anti-HIV activity of intravenous
nystatin in patients with HIV infection who have completed protocol FDA 103C. To evaluate
the safety and potential antiviral activity of intravenous nystatin and oral didanosine
(ddI) administered in an alternating regimen in this patient population.
A Phase I/II Clinical Study of Nystatin I.V. (Intravenous) in Patients With HIV Infection. [Completed]
To evaluate the clinical toxicity, safety, and maximum tolerated dose (MTD) of intravenous
nystatin in patients with HIV infection. To evaluate the potential anti-HIV activity and
clinical pharmacology of intravenous nystatin.
|
